Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    NCT01683149
Show Display Options
Rank Status Study
1 Active, not recruiting Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies
Condition: Solid Tumor
Interventions: Drug: Topotecan;   Drug: Sorafenib

Indicates status has not been verified in more than two years